Eli Lilly Catches Up with Mounjaro Shortage

Eli Lilly announced it caught up on backorders for its obesity drug Mounjaro, drawing the end near for a shortage that’s persisted since last December. Some patients may still have to wait for the drug, but delays will likely drop to one to two days. The drug is still on the US Food and Drug Administration’s drug shortage supply list, which may change in the coming days.

According to Angus Liu, “Demand for Mounjaro surged following impressive weight reduction data in an obesity trial. Supply constraints for Novo Nordisk’s rival diabetes and weight loss drugs, Ozempic and Wegovy, as well as a social media craze over these drugs, further fueled interest in Mounjaro. The Novo drugs are both made with the GLP-1 agonist semaglutide, while Mounjaro is tirzepatide, a dual GIP/GLP-1 agonist.”

To read more, click here.

(Source: Fierce Pharma, February 22^nd, 2023)